Northfield Bancorp, Inc.
Northfield Bancorp, Inc. (NASDAQ: NFBK) related to its merger with Columbia Financial, Inc.
Northfield Bancorp, Inc. (NASDAQ: NFBK) related to its merger with Columbia Financial, Inc.
Columbia Financial, Inc. (NASDAQ: CLBK) related to its merger with Northfield Bancorp, Inc.
Coterra Energy, Inc. (NYSE: CTRA) related to its sale to Devon Energy Corporation. Under the terms of the proposed transaction, Coterra shareholders will receive 0.70 of a share of Devon common stock for each share of Coterra common stock.
Devon Energy Corporation (NYSE: DVN) related to its merger with Coterra Energy, Inc. Under the terms of the proposed transaction, Devon shareholders will own approximately 54% of the combined company.
Stellar Bancorp, Inc. (NYSE: STEL) related to its sale to Prosperity Bancshares, Inc. Under the terms of the proposed transaction, Stellar shareholders are expected to receive 0.3803 shares of Prosperity common stock and $11.36 in cash for each share of Stellar common stock.
Gold Resource Corporation (NYSE: GORO) related to its sale to Goldgroup Mining, Inc. Under the terms of the proposed transaction, Gold Resource shareholders are expected to have their shares converted into 1.4476 common shares of Goldgroup.
Skywater Technology, Inc. (NASDAQ: SKYT) related to its sale to IonQ, Inc. Under the terms of the proposed transaction, Skywater shareholders are expected to receive $15.00 per share in cash and $20.00 in shares of IonQ common stock.
Lisata Therapeutics, Inc. (NASDAQ: LSTA) related to its sale to Kuva Labs, Inc. Under the terms of the proposed transaction, Lisata shareholders are expected to receive $4.00 per share in cash, and one non-transferable contingent value right entitling Lisata shareholders to receive potential payments under certain conditions.
Nathan’s Famous, Inc. (NASDAQ: NATH) related to its sale to Smithfield Foods, Inc. Under the terms of the proposed transaction, Nathan’s shareholders are expected to receive $102.00 per share in cash.
RAPT Therapeutics, Inc. (NASDAQ: RAPT) related to its sale to GSK plc. Under the terms of the proposed transaction, RAPT shareholders are expected to receive $58.00 in cash for each share of RAPT common stock.